UPDATE 1-Biogen to spin off hemophilia drug business into a public company

May 3 (Reuters) - Biogen Inc said on Tuesday it

would spin off its hemophilia drug business as a publicly traded

company in a tax-free transaction, leaving the drugmaker to

focus on developing drugs for neurodegenerative diseases.

Read more